|
Dr. Hellmann is the interim director of the HIV, TB, and Reproductive Health initiative. In this capacity, he is responsible for research, program and policies related to HIV/AIDS, sexually transmitted diseases, reproductive health issues and tuberculosis for the foundation.
Prior to joining the foundation, Hellmann was the Chief Medical Officer at Roche Molecular Systems, the global leader in the development of nucleic acid-based diagnostic tests for individualized clinical management of human diseases. Prior to that position, Hellmann was the Vice President of Clinical Research at ViroLogic, Inc from 1997-2003, a leading company in the development of therapy guidance technologies related to evaluation and management of drug resistance in serious viral infections, such as HIV and hepatitis. Prior to joining ViroLogic, Hellmann held positions at biotechnology and pharmaceutical companies, including Gilead Sciences, Genentech, and Bristol-Myers Squibb, where he directed clinical research activities related to the development of novel antiviral and antimicrobial drugs.
After receiving his M.D. degree from the University of Kentucky in 1982, Hellmann completed his Internal Medicine Residency and Infectious Diseases Fellowship training at the University of California, San Francisco. After completion of his fellowship training in 1988, Hellmann was an Assistant Professor in the Internal Medicine/Infectious Diseases Division at the University of California, San Francisco and was an infectious diseases consultant in a private medical practice. While on the Department of Medicine Faculty at UCSF, Dr Hellmann lived and worked in Uganda, East Africa from 1989-1991 on a research project to identify risk factors, such as STIs, circumcision status, and sexual behaviors, associated with heterosexual transmission of HIV infection and to develop appropriate intervention strategies to reduce HIV transmission. | 